MorphicLogo.jpg
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 08:00 ET | Morphic Therapeutic
First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
April 10, 2021 08:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:30 ET | Gennao Bio
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
April 10, 2021 08:30 ET | Achilles Therapeutics PLC
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
April 09, 2021 09:00 ET | Sana Biotechnology, Inc
– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in...
Rubius_Logo.jpg
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
April 09, 2021 08:00 ET | Rubius Therapeutics
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Atyr_Logo.png
aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting
April 09, 2021 08:00 ET | aTyr Pharma, Inc.
Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Abstract at AACR
March 23, 2021 08:00 ET | Cancer Advances Inc
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces that an abstract...
RevolutionLogo.png
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
March 11, 2021 13:16 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...